Trials / Recruiting
RecruitingNCT05890417
Evolution of Sexual Life Quality of Women With POI Before and After Introduction of Hormone Replacement Therapy
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 135 (estimated)
- Sponsor
- University Hospital, Bordeaux · Academic / Other
- Sex
- Female
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the evolution of quality of sex life of women with POI after introduction hormone replacement therapy through the FSFI scale
Detailed description
Premature ovarian failure (POI) is a pathology that affects about 1-2% of women before the age of 40. The resulting estrogen deficiency is the cause of multiple repercussions. Clinically, sexual disorders may appear in the short term, such as a decrease in libido, vaginal dryness, an increase in dyspareunia, resulting in less frequent sexual intercourse and less satisfaction with sexual life. The quality of life of these patients also appears to be reduced compared to women with normal ovarian reserve. A 2008 study showed that the sexual function of patients with POI treated with hormone replacement therapy (HRT) was normal but remained significantly lower than that of patients with normal ovarian function. However, no study has attempted to assess the evolution of the symptomatology of these patients before and after the introduction of HRT. Evidence of improvement in sexual disorders under treatment could be an additional argument to improve patient adherence and treatment compliance; as well as information for health professionals
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | questionnaire | Female Sexual Function Index (FSFI) and WHO Quality of Life-BREF (WHOQOL-BREF) questionnaires at baseline and 6 months after starting hormone replacement therapy |
Timeline
- Start date
- 2023-07-17
- Primary completion
- 2027-06-01
- Completion
- 2027-06-01
- First posted
- 2023-06-06
- Last updated
- 2025-09-09
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05890417. Inclusion in this directory is not an endorsement.